IP Verse

Greiner patent opposition analysis

The comprehensive analysis of Greiner opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Latest patent oppositions filed by Greiner

Stay updated with the latest patent oppositions filed by Greiner

Patent NumberTitleApplicantOpposition DateOpposition Company
EP3858859
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 27, 2026GREINER
EP3411021
New Use Of A Combination Of Sacubitril And ValsartanNOVARTISFeb 13, 2026ZENTIVA KS
EP4212152
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISJan 30, 2026ZENTIVA
EP4125903
Methods For Dose Initiation Of Aripiprazole TreatmentsOTSUKA PHARMACEUTICALJul 9, 2025ZENTIVA
EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJun 25, 2025ZENTIVA KS
EP3815688
Pharmaceutical Composition Containing Poorly-Soluble Basic MedicineCHUGAI SEIYAKU KABUSHIKI KAISHASep 6, 2024SANDOZ
EP3626270
New UseNOVARTISJul 11, 2024ZENTIVA KS
EP3294283
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISDec 8, 2023ZENTIVA
EP3345607
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSTEOQCJul 26, 2023AMGEN EUROPE
EP3827845
Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their UsesJANSSEN BIOTECHDec 27, 2022KONIG SZYNKA TILMANN VON RENESSE

Top clients of Greiner

Top companies who are the clients of Greiner

CompanyTotal
ZENTIVA8
GREINER7
ZENTIVA KS5
TEVA PHARMACEUTICALS3
DF MP DRRIES FRANK MOLNIA & POHLMAN3
DF MP DORRIES FRANK MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBB3
PHARMA STULLN2
SANDOZ2
ZENTIVA GROUP1
HEXAL1